Braxia Scientific Corp.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Peter Rizakos
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1430 Hurontario Street Mississauga ON Canada L5G 3H4
- IPO Date
- Mar 25, 2020
- Website
- braxiascientific.com
- Similar Companies
- Business
- Braxia Scientific Corp. operates as a medical research and telemedicine company focused on brain-based mental disorders, including major depressive disorder, through its clinics offering ketamine-based treatments; psilocybin derivatives and other psychedelic products developed from its intellectual property platform; and virtual care services via the KetaMD telemedicine platform for at-home ketamine administration. The company, founded in 2020 and headquartered at 700 Bay Street, Suite 1903, Toronto, Ontario, Canada, previously owned and operated multidisciplinary clinics in Canada under its wholly-owned subsidiary Canadian Rapid Treatment Center of Excellence Inc., with locations in Mississauga, Toronto, Ottawa, and Montreal, targeting patients with treatment-resistant depression and bipolar disorder. Braxia Scientific conducts research to discover and commercialize novel drugs and delivery methods for mental health disorders, primarily serving North American markets with in-person and virtual treatments. In November 2024, the company completed the sale of substantially all its assets, including the Canadian Rapid Treatment Center of Excellence Inc., to Kris Kratiuk, leaving it with minimal cash, a working capital deficiency exceeding $1.8 million, and only the KetaMD platform intellectual property as a remaining asset. Following a failure-to-file cease trade order from the Ontario Securities Commission in August 2024 due to delayed financial filings, trading was suspended on the Canadian Securities Exchange with delisting imminent, and Braxia Scientific now plans to wind down operations after addressing staff obligations, with no further business pursuits intended.
Braxia Scientific Update
Braxia Scientific Announces Change in Directors and CEO
Braxia Scientific Announces Voting Results from the Annual General and Special Meeting of Shareholders
Braxia Announces Annual General and Special Meeting
Braxia Scientific Announces Cease Trade Order
Braxia Scientific Provides Update on Application for Management Cease Trade Order
Braxia Scientific Announces Application for a Management Cease Trade Order For Late Filing of Audited Annual Financial Statements
Braxia Scientific Reports Q3 2024 Financial Results
Braxia Scientific Reports Mandatory Conversion of Debentures
Braxia Scientific Reports Q2 2024 Financial Results and Provides Corporate Update
Braxia Scientific Reports Q1 Fiscal 2024 Financial Results
Braxia Scientific Reports Fiscal 2023 Financial Results
Braxia Scientific reports significant increase in treatment volumes across its clinics
Braxia Scientific announces termination of Irwin Naturals merger LOI; retains strategic clinical assets
Braxia Scientific reports 50.5% increase in 3Q revenue; updates on acquisition by Irwin Naturals
Braxia Scientific closes first tranche of its non-brokered offering for aggregate proceeds of $751,218.83
Braxia Scientific announces up to $1.5M offering and concurrent private placement
Irwin Naturals announces LOI to acquire Braxia Scientific to create new market leader
Irwin Naturals an Braxia Scientific partner to accelerate in-human development of new therapies for mental health
Braxia Scientific sees Q2 revenue increase, with in-clinic treatment up 34.5%